No profile data available.
NewAmsterdam Pharma Company N.v. (NAMS) is a healthcare company in the metabolic process treatment drugs industry, based in Naarden, Netherlands, with about 100 full-time employees.
It reported revenue of $22.50 million for fiscal year 2025, down 50.6% from fiscal year 2024, and net income of -$203.82 million. Its market capitalization was $2.58 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NewAmsterdam Pharma reported $22.50 million in revenue for fiscal year 2025, down 50.6% from $45.56 million in fiscal year 2024.
$2.58 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include BioMarin Pharmaceutical Inc. (BMRN), Disc Medicine, Inc. (IRON), Maze Therapeutics, Inc. (MAZE), Zevra Therapeutics, Inc. (ZVRA).